pH-feedback controlled infusions of ranitidine are no more effective than fixed-dose infusions in reducing gastric acidity and variability in antisecretory responses
- PMID: 1524960
- PMCID: PMC1381434
- DOI: 10.1111/j.1365-2125.1992.tb04075.x
pH-feedback controlled infusions of ranitidine are no more effective than fixed-dose infusions in reducing gastric acidity and variability in antisecretory responses
Abstract
1. The antisecretory responses to pH-feedback controlled (maximum dose 800 mg 24 h-1) and fixed-dose (0.25 mg kg-1 h-1) continuous infusions of ranitidine were compared in a randomised, placebo-controlled, cross-over study in 10 healthy male volunteers. 2. To assess tolerance during repeated dosing with ranitidine, the same infusion regimens were given before and after 6 days oral dosing with ranitidine 300 mg four times daily. 3. With the pH-feedback controlled infusion of ranitidine the median % time (interquartile range) with pH greater than 4 in the 24 h period was 57% (45-76) before and 23% (17-34) after 6 days oral dosing (P less than 0.001). The respective values with fixed-dose infusion were 51% (38-63) and 26% (15-32) (P less than 0.002). 4. The median 24 h doses (interquartile range) of ranitidine given by feedback-controlled infusion before and after 6 days oral dosing were 675 mg (542-728) and 749 mg (709-760), respectively (P less than 0.01). The dose of ranitidine given by fixed-rate infusion was 423 mg (393-502) on both study days (P less than 0.001 vs feedback infusion). 5. Plasma gastrin concentrations remained slightly elevated after 6 days of oral ranitidine dosing, whereas pancreatic polypeptide plasma levels remained unchanged. 6. The antisecretory efficacy of infusions of ranitidine is significantly decreased by circadian stimuli and tolerance. Individually-adapted infusions of high doses of ranitidine were not superior to fixed-dose infusion of 0.25 mg kg-1 h-1 in overcoming this variability.
Similar articles
-
Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine.Gastroenterology. 1993 Sep;105(3):748-54. doi: 10.1016/0016-5085(93)90892-g. Gastroenterology. 1993. PMID: 8103027 Clinical Trial.
-
Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.Aliment Pharmacol Ther. 1994 Apr;8(2):193-201. doi: 10.1111/j.1365-2036.1994.tb00278.x. Aliment Pharmacol Ther. 1994. PMID: 8038351 Clinical Trial.
-
Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?Gastroenterology. 1994 Jan;106(1):60-4. doi: 10.1016/s0016-5085(94)94341-9. Gastroenterology. 1994. PMID: 8276209 Clinical Trial.
-
Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours.Am J Gastroenterol. 1999 Feb;94(2):351-7. doi: 10.1111/j.1572-0241.1999.857_y.x. Am J Gastroenterol. 1999. PMID: 10022628 Clinical Trial.
-
Tolerance during 5 months of dosing with ranitidine, 150 mg nightly: a placebo-controlled, double-blind study.Gastroenterology. 1991 Oct;101(4):948-53. doi: 10.1016/0016-5085(91)90720-6. Gastroenterology. 1991. PMID: 1889719 Clinical Trial.
Cited by
-
Individual and group dose-responses to intravenous omeprazole in the first 24 h: pH-feedback-controlled and fixed-dose infusions.Br J Clin Pharmacol. 1995 Jan;39(1):15-23. doi: 10.1111/j.1365-2125.1995.tb04404.x. Br J Clin Pharmacol. 1995. PMID: 7756094 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources